Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Concentric Analgesics.

    Client Virtual Booth

    CONCENTRIC ANALGESICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Concentric Analgesics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    101 California Street, Suite 1210 San Francisco, CA 94111
    Telephone
    Telephone
    415.484.7921
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.concentricanalgesics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/concentric-analgesics-inc-/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Concentric Analgesics Announces Positive Results from Pilot Phase 2 Clinical Trial of Vocacapsaicin in Open Laparotomy for Repair of Abdominal Ventral H...

    Details:

    The pilot study showed that vocacapsaicin, administered during surgery at a dose of 24 mg (0.3 mg/mL solution), reduced pain after coughing by 46% compared to the placebo control during the first 96 hours after surgery (p=0.02).


    Lead Product(s): Vocacapsaicin

    Therapeutic Area: Gastroenterology Product Name: CA-008

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor

    Details:

    The company has entered into a formal agreement with Evolution Research Group (ERG), a leading postsurgical pain clinical research site network in the U.S., to conduct its registration trials with CA-008 (vocacapsaicin).


    Lead Product(s): Vocacapsaicin,Ketorolac Trometamol,Paracetamol

    Therapeutic Area: Neurology Product Name: CA-008

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Evolution Research Group

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement February 02, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor

    Details:

    URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin’s benefit to patient recovery and rehabilitation.


    Lead Product(s): Vocacapsaicin,Ketorolac Trometamol,Paracetamol

    Therapeutic Area: Neurology Product Name: CA-008

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: University of Rochester Medical Center

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 02, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling ...

    Details:

    Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.


    Lead Product(s): Vocacapsaicin,Ketorolac Trometamol,Paracetamol

    Therapeutic Area: Neurology Product Name: CA-008

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: $20.0 million Upfront Cash: Undisclosed

    Deal Type: Financing January 26, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search